[1] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145-58.
[2] Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011;42(12):3651-4.
[3] Benjamin E J, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 Update: A report from the American Heart Association. Circulation. 2019;139(10): e56-e28.
[4] Larsson S C, Burgess S, Michaëlsson, K. Smoking and stroke: A mendelian randomization study. Ann Neurol. 2019;86(3):468-71.
[5] Lee J S, Chang P Y, Zhang Y, et al. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: The Strong Heart Study. Diabetes Care. 2017;40(4):529-37.
[6] Yong H, Foody J, Linong J, et al. A systematic literature review of risk factors for stroke in China. Cardiol Rev. 2013;21(2):77-93.
[7] Fahimfar N, Khalili D, Mohebi R, et al. Risk factors for ischemic stroke; results from 9 years of follow-up in a population-based cohort of Iran. BMC Neurol. 2012;12(1):117.
[8] Anderson CD, Biffi A, Rost NS, et al. Chromosome 9p21 in ischemic stroke: population structure and meta-analysis. Stroke. 2010;41(6):1123-31.
[9] Hsu WC, Chen ST, Wu YR, et al. The association of stroke and family history of stroke depends on its subtypes and gender: a family history study in Taiwan. Acta Neurol Taiwan. 2009;18(3):161-9.
[10] Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med. 2009;360(17):1718-28.
[11] Jood K, Ladenvall C, Rosengren A, et al. Family history in ischemic stroke before 70 years of age. Stroke. 2005;36(7):1383-7.
[12] Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke. 2002;33(3):769-74.
[13] Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298-307.
[14] Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154(1):26-46.
[15] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10(3):155-9.
[16] Zhang J, Yuan L, Zhang X, et al. Altered long non-coding RNA transcriptomic profiles in brain microvascular endothelium after cerebral ischemia. Exp Neurol. 2016;277: 162-170.
[17] Wang C, Qu Y, Suo R, Zhu, Y. Long non-coding RNA MALAT1 regulates angiogenesis following oxygen-glucose deprivation/reoxygenation. J Cell Mol Med. 2019;23(4): 2970-83.
[18] Li Z, Li J, Tang N. Long noncoding RNA malat1 is a potent autophagy inducer protecting brain microvascular endothelial cells against oxygen-glucose deprivation/reoxygenation-induced injury by sponging miR-26b and upregulating ULK2 expression. Neuroscience. 2017;354:1-10.
[19] Zhang X, Tang X, Liu K, et al. Long noncoding RNA malat1 regulates cerebrovascular pathologies in Ischemic stroke. J Neurosci. 2017;37(7):1797-1806.
[20] Wei Y S, Yang J, He Y L, et al. A functional polymorphism in the promoter of TUG1 is associated with an increased risk of ischaemic stroke. J Cell Mol Med. 2019;23(9): 6173-81.
[21] Yang J, Gu L, Guo X, et al. LncRNA ANRIL expression and ANRIL gene polymorphisms contribute to the risk of ischemic stroke in the Chinese Han population. Cell Mol Neurobiol. 2018; 38(6):1253-69.
[22] Wang J, Cao B, Han D, et al. Long non-coding RNA H19 induces cerebral ischemia reperfusion injury via activation of autophagy. Aging Dis. 2017;8(1):71-84.
[23] Masson E, Chen JM, Cooper DN, Férec, C. PRSS1 copy number variants and promoter polymorphisms in pancreatitis: common pathogenetic mechanism, different genetic effects. Gut. 2018;67(3):592-3.
[24] Fischer J, Weber A, Böhm, S, et al. Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut. 2017;66(10):1829-1837.
[25] Wang BG, Xu Q, Lv Z, et al. Association of twelve polymorphisms in three onco-lncRNA genes with hepatocellular cancer risk and prognosis: A case-control study. World J Gastroenterol. 2018;24(23):2482-90.
[26] Wang JZ, Xiang JJ, Wu LG, et al. A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis. BMC Cancer. 2017;17(1):167.
[27] Zhuo Y, Zeng Q, Zhang P, et al. Functional polymorphism of lncRNA MALAT1 contributes to pulmonary arterial hypertension susceptibility in Chinese people. Clin Chem Lab Med. 2017;55(1):38-46.
[28] Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non -small cell lung cancer. Oncogene. 2003;22(39):8031-41.
[29] Gast M, Rauch BH, Nakagawa S, et al. Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-/-mice. Cardiovasc Res. 2019;115(2):302-14.
[30] Zhang X, Hamblin MH, Yin K. The long noncoding RNA malat1: Its physiological and pathophysiological functions. RNA Biol. 2017;14(12):1705-14.
[31] Arun G, Diermeier S, Akerman M, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30(1):34-51.
[32] Hirata H, Hinoda Y, Shahryari V, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322-31.
[33] Cremer S, Michalik KM, Fischer A, et al. Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation. Circulation. 2019;139(10):1320-34.
[34] Li S, Sun Y, Zhong L, et al. The suppression of ox-LDL-induced inflammatory cytokine release and apoptosis of HCAECs by long non-coding RNA-MALAT1 via regulating microRNA-155/SOCS1 pathway. Nutr Metab Cardiovasc Dis. 2018;28(11):1175-1187.
[35] Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014;114(9):1389-97.
[36] Thum T, Fiedler J. LINCing MALAT1 and angiogenesis. Circ Res. 2014;114(9): 1366-8.
[37] Zhao K, Jin S, Wei B, et al. Association study of genetic variation of lncRNA MALAT1 with carcinogenesis of colorectal cancer. Cancer Manag Res. 2018;10:6257-61.
[38] Li Y, Bao C, Gu S, et al. Associations between novel genetic variants in the promoter region of MALAT1 and risk of colorectal cancer. Oncotarget. 2017;8(54):92604-92614.
[39] Peng R, Luo C, Guo Q, et al. Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene. 2018;642:241-8.
[40] Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016; 29(4):452-63.
[41] Hu W, Ding H, Ouyang A, et al. LncRNA MALAT1 gene polymorphisms in coronary artery disease: a case-control study in a Chinese population. Biosci Rep. 2019;39(3). doi:10.1042/BSR20182213.